Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 15/20 | 0.36 |
| ▸ | RICTOR | Q6R327 | 15/20 | 0.36 |
| ▸ | MAPKAP1 | Q9BPZ7 | 15/20 | 0.36 |
| ▸ | MLST8 | Q9BVC4 | 15/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.33 |
| ▸ | STK4 | Q13043 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15218929 | 0.92 | MTOR (0.36) | MTORRICTORMAPKAP1MLST8CYP2C8 | |
| SCHEMBL15218933 | 0.90 | STK4 (0.37) | MTORRICTORMAPKAP1MLST8CYP2C8 | |
| SCHEMBL15218902 | 0.85 | MTOR (0.35) | MTORRICTORMAPKAP1MLST8CYP2C8 | |
| SCHEMBL15218884 | 0.85 | STK4 (0.41) | STK4 | |
| SCHEMBL15218892 | 0.81 | PRKDC (0.35) | STK4 | |
| SCHEMBL15218931 | 0.80 | SMN1; SMN2 (0.32) | MTORRICTORMAPKAP1MLST8 | |
| SCHEMBL15218894 | 0.79 | MTOR (0.38) | MTORRICTORMAPKAP1MLST8RPTOR | |
| SCHEMBL15218922 | 0.78 | PSEN1 (0.41) | MTORRICTORMAPKAP1MLST8RPTOR | |
| SCHEMBL15218886 | 0.78 | MTOR (0.37) | MTORRICTORMAPKAP1MLST8 | |
| SCHEMBL15218893 | 0.78 | STK4 (0.40) | STK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2958918-B1 | DIHYDROPTERIDINONES II | BOEHRINGER INGELHEIM INT (DE) | 2016-12-07 | — | — | EP | disclosed |
| US-8865716-B2 | Dihydropteridinones II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-8865716-B2 | Dihydropteridinones II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| WO-2014127816-A1 | DIHYDROPTERIDINONES II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-28 | — | — | WO | disclosed |
| US-20130225593-A1 | DIHYDROPTERIDINONES II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225593-A1 | DIHYDROPTERIDINONES II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225593-A1 | DIHYDROPTERIDINONES II | BACE1, BACE2, APP | MTOR 850/4885RICTOR 3123/4885MAPKAP1 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.